QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 限定条件 发表日期：2021     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor. 期刊论文 CANCER RESEARCH, 2021, 卷号: 81, 期号: 13, 页码: 1 作者:  Brandhuber, Barbara;  Ku, Karin;  Lallena, Maria J.;  Baquero, Carmen;  Choy, Regina 收藏  |  浏览/下载：12/0  |  提交时间：2021/11/04 Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu 收藏  |  浏览/下载：19/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor   TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models 期刊论文 AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 卷号: 11, 期号: 4, 页码: 1632-1645 作者:  Wang, Lei;  Zhu, Xi;  Li, Lili;  Li, Lin;  Fu, Li 收藏  |  浏览/下载：75/0  |  提交时间：2021/06/11 PARP  DNA damage  hematologic toxicity  beta-glucuronidase  tumor selectivity